Sanders Bill Would Allow Biosimilar “Pay-For-Data” System
Executive Summary
Biosimilar manufacturers could buy access to existing clinical trial data to use in their applications and avoid conducting some clinical trials, if a bill filed by Sen. Bernard Sanders, I-Vt., is approved.
You may also be interested in...
Biosimilar Application Pathway Likely To Travel Through Courts
The courts likely will get involved in biosimilars even if FDA decides which application pathway a biosimilar would travel, a consultant and former FDA official said.
Biosimilar Application Pathway Likely To Travel Through Courts
The courts likely will get involved in biosimilars even if FDA decides which application pathway a biosimilar would travel, a consultant and former FDA official said.
Biosimilars May Drift, But What Should FDA Do About It?
Another balance FDA likely will have to strike in its emerging biosimilars pathway is letting innovators improve and update manufacturing processes while ensuring similar biologics can remain similar to their reference products.